Search is Powered by Google
Multiple Sclerosis News

Regulatory Immune Cells Not Defective In Multiple Sclerosis

Main Category: Multiple Sclerosis
Also Included In: Immune System / Vaccines
Article Date: 04 Sep 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 stars

3.69 (13 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Multiple sclerosis (MS) is a chronic inflammatory disease that causes neurodegeneration, resulting in numerous physical and mental disabilities. It is thought to be caused by out of control immune cells that attack the proteins that make up the protective sheath in which nerve cells are encased. In addition, it has been reported that a subset of immune cells known as Tregs (characterized by expression of the protein CD4 and high levels of expression of the protein CD25), which suppresses the function of aggressive immune cells, is defective in individuals with MS, and that this contributes to the progression of the disease. However, it has recently been shown that if CD4+CD25high cells are divided into cells expressing high and low levels of the protein CD127 only the CD4+CD25highCD127low cells have suppressive capability. Thus, Jean-Paul Soulillou and colleagues, at INSERM U643, France, compared the suppressive capabilities of CD4+CD25highCD127low cells from individuals with MS and healthy individuals. Surprisingly, they found that these cell populations were equally effective suppressors of aggressive immune cells when analyzed in vitro. These data therefore indicate that the suppressive function of Tregs (when characterized as CD4+CD25highCD127low) is not defective in individuals with MS, suggesting that this defective Treg function is not a factor that contributes to the development of this debilitating autoimmune disease.

TITLE: Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis

AUTHOR:

Jean-Paul Soulillou
INSERM U643, Nantes, France.
http://www.univ-nantes.fr

View the PDF of this article at: https://www.the-jci.org/article.php?id=35365

Source:
Karen Honey
Journal of Clinical Investigation




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

An MS Drug Back on the Market image An MS Drug Back on the Market

After being suspended from the market for safety reasons, natalizumab is again available for the treatment of multiple sclerosis. Safeguards are in place because of a small risk in developing a serious brain infection. Should you consider taking this drug...

View more videos...